Market Spotlight: Irritable Bowel Syndrome (IBS)
発行: Datamonitor Healthcare
ページ情報: 英文 50 Pages
当レポートでは、過敏性大腸症候群 (IBS) の治療薬市場について分析し、疾患の概要や患者数の推移・見通し、現段階での主な治療法、規制環境と近年の主な出来事、現在開発中の治験の進行状況と上市スケジュール、主な治療薬の市場動向見通し (今後10年間分)、資本取引の動きなどを調査しております。
This Market Spotlight report covers the irritable bowel syndrome (IBS) market, comprising key pipeline and marketed drugs, clinical trials, upcoming regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2017, there were approximately 766 million prevalent cases of irritable bowel syndrome (IBS) in people aged 15 years and over worldwide, and forecasts that number to increase to 843 million prevalent cases by
2026. The approved drugs in the IBS space target chloride channel 2, calcium channel, sodium-hydrogen exchanger 3, serotonin 5- HT3 receptor, guanylyl cyclase c receptor, opioid receptors, gram-negative bacteria, RNA polymerase, and serotonin 5-HT4 receptor. These drugs are administered via the oral route.
The majority of industry-sponsored drugs in active clinical development for IBS are in Phase II.
Therapies in development for IBS focus on a wide variety of targets. All of the pipeline drugs are administered via the oral route.
The only high-impact upcoming event in the IBS space is the release of topline Phase II trial results for MD-7246. The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 21.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.6 years in the overall gastroenterology (non inflammatory bowel disease) space.
There have been 20 licensing and asset acquisition deals involving IBS drugs during 2014-19. The $2,905m research, development, collaboration, and license agreement signed in 2017 between Allergan and Assembly Biosciences for the worldwide rights to Assembly's microbiome GI development programs was the largest deal.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for IBS have been in the early and midphases of development, with 65% of trials in Phase I-II, and only 35% in Phase III-IV.
The US has a substantial lead in the number of IBS clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
Clinical trial activity in the IBS space is dominated by completed trials. Allergan and GlaxoSmithKline have the highest number of completed clinical trials for IBS, with 37 trials each.
Allergan leads industry sponsors with the highest number of clinical trials for IBS, followed by GlaxoSmithKline.
9 Antidiarrheal drugs
9 Serotonin receptor agonists
10 Chloride channel activators
10 Guanylyl cyclase C agonists
10 Opioid receptors
27 Zelnorm for IBS (July 8, 2019)
27 Multiple Drugs for IBS (June 25, 2019)
28 Linzess for IBS (June 18, 2019)
30 IB-Stim for IBS (June 7, 2019)
31 Zelnorm for IBS (October 17, 2018)
32 Zelnorm for IBS (October 15, 2018)
36 Ardelyx Touts Ibsrela's Novel Mechanism Of Action For IBS-C
36 FDA Approves The First Device To Treat Pain Caused By IBS
36 Poland Switches from Rx-To-OTC Mylan's Duspatalin For IBS, Plus Orion's ED Treatment
36 Zelnorm Returning To US Market With Broad IBS-C Indication
39 AstraZeneca Acquires All Linzess Rights In China
39 Alfasigma Acquires Sloan's Zelnorm
40 Deals Shaping The Medical Industry, January 2019
44 Sponsors by status
45 Sponsors by phase
48 Prescription information